Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2341 to 2355 of 9128 results

  1. Veligrotug for treating thyroid eye disease [ID6636]

    Awaiting development Reference number: GID-TA11839 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Laroprovstat for treating primary hypercholesterolaemia or mixed dyslipidaemia disease

    Awaiting development Reference number: GID-TA12477 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Vamikibart for treating uveitic macular oedema ID6671

    In development Reference number: GID-TA11885 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development Reference number: GID-TA11501 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 March 2027

    NICE guideline
    In development

  6. Radiofrequency ablation of the basivertebral nerve for chronic low back pain

    Awaiting development Reference number: GID-HTG10871 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  7. Taletrectinib for treating ROS1-positive advanced non-small-cell lung cancer

    Awaiting development Reference number: GID-TA12467 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Cryoablation for Desmoid-type Fibromatosis

    Awaiting development Reference number: GID-HTG10872 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  9. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-HTG10870 Expected publication date:  15 October 2026

    HealthTech guidance
    In development

  10. Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]

    In development Reference number: GID-TA11766 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Transverse tibial transport for diabetic foot ulceration

    Awaiting development Reference number: GID-HTG10873 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  12. Heart valve disease presenting in adults: investigation and management - transcatheter aortic valve implantation (TAVI) to treat aortic stenosis (update)

    In development Reference number: GID-NG10457 Expected publication date: TBC

    NICE guideline
    In development

  13. Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]

    In development Reference number: GID-TA11638 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]

    Awaiting development Reference number: GID-TA11978 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]

    In development Reference number: GID-TA11818 Expected publication date:  14 April 2027

    Technology appraisal guidance
    In development